Company intelligence / Profile preview

Angiotensin Therapeutics Inc.

Evanston, Illinois, United Statesangiotx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a novel soluble ACE2 variant with prolonged duration of action that can neutralize SARS-CoV-2. Their ACE2 variants have been modified to increase duration of action from hours to days, making them more suitable therapeutically. Preclinical studies have shown promise for COVID-19 treatment by intercepting the virus from reaching ACE2 receptors in cell membranes.

Therapeutic areas: Infectious DiseasesNephrology
Modalities: BiologicsACE2 enzyme variants
Industry: Biotech

Drug pipeline

3 assets

AGT003

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Northwestern University

Beyond the preview

Go deeper on Angiotensin Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angiotensin Therapeutics Inc..

Explore the full profile